

Supplementary Material

Multifaceted mechanisms of WY-14643 to stabilize the blood-brain barrier during cerebral ischemia

Winfried Neuhaus*, Tobias Krämer, Anja Neuhoff, Christina Gölz, Serge C. Thal, Carola Y. Förster

* Correspondence: Winfried Neuhaus: winfried.neuhaus@ait.ac.at

Supplementary tables:

1ST: Taqman probes used for qPCR analysis

| Target | Taqman [®] probe identification number |
|----------------|---|
| Abcb1a | Mm00440761_m1 |
| Abcc4 | Mm01226380_m1 |
| Abcg2 | Mm00496364_m1 |
| Angiopoietin-2 | Mm00545822_m1 |
| β-actin | Mm01205647_g1 |
| Caveolin-1 | Mm00483057_m1 |
| Claudin-1 | Mm00516701_m1 |
| Claudin-3 | Mm00515499_s1 |
| Claudin-4 | Mm00515514_s1 |
| Claudin-5 | Mm00727012_s1 |
| Claudin-12 | Mm01316511_m1 |
| Hif1a | Mm00468869_m1 |
| ICAM-1 | Mm00516023_m1 |
| Kdr (VEGFR2) | Mm00440099_m1 |
| Lrp1 | Mm00464608_m1 |
| MMP-2 | Mm00439498_m1 |

| | - |
|------------------|---------------|
| MMP-3 | Mm00440295_m1 |
| MMP-9 | Mm00442991_m1 |
| Neuropilin-1 | Mm00435379_m1 |
| Occludin | Mm00500912_m1 |
| Plat (t-PA) | Mm00476931_m1 |
| Serpine1 (PAI-1) | Mm00435860_m1 |
| Serpine F2 | Mm00435868_m1 |
| SOD | Mm01344233_g1 |
| Tek (Tie-2) | Mm00443243_m1 |
| Timp1 | Mm00441818_m1 |
| Timp3 | Mm00441826_m1 |
| Tjp1 (ZO-1) | Mm01320637_m1 |
| Vegfa | Mm01281449_m1 |
| Angpt1 | Rn00585552_m1 |
| АроЕ | Rn04219668_g1 |
| GDNF | Rn00569510_m1 |
| PDGFb | Rn01502596_m1 |
| Plat (t-PA) | Rn01482578_m1 |
| Serpine1 (PAI-1) | Rn01481341_m1 |
| ΤΝFα | Rn01525859_g1 |

| Target | Product number, Company | Species | Application dilution |
|---|--|---------|----------------------|
| Akt1/2/3 | sc-8312, Santa Cruz | rabbit | 1:200 for WB |
| pAkt | #4060, Cell Signaling TECHNOLOGY® | rabbit | 1:100 for WB |
| Erk1/2 | #9102, Cell Signaling TECHNOLOGY® | rabbit | 1:200 for WB |
| phospho-Erk1/2 | #9101, Cell Signaling TECHNOLOGY® | rabbit | 1:200 for WB |
| p38 | #9212, Cell Signaling TECHNOLOGY® | rabbit | 1:1000 for WB |
| phospho-p38 | #9211, Cell Signaling TECHNOLOGY® | rabbit | 1:1000 for WB |
| SAPK/JNK | #9252, Cell Signaling TECHNOLOGY® | rabbit | 1:200 for WB |
| phospho-SAPK/JNK | #9251, Cell Signaling TECHNOLOGY® | rabbit | 1:50-1:100 for WB |
| Claudin-5 | 34-1600, Zymed [®] , Invitrogen | rabbit | 1:200 for WB |
| Lamin-A | ab8980 [133A2], Abcam | mouse | 1:100 for IF |
| Na ⁺ /K ⁺ -ATPase | sc-28800, Santa Cruz | rabbit | 1:100 for WB |
| Occludin | 71-1500, Zymed [®] , Invitrogen | rabbit | 1:200 for WB |
| PAI-1 | ab28207, Abcam | rabbit | 1:100 for WB |
| ΡΡΑRα | sc9000, Santa Cruz (H-98), | rabbit | 1:100 for IF |
| t-PA | ab62763, Abcam | rabbit | 1:150 for WB |
| ZO-1 | 40-2300, Zymed [®] , Invitrogen | rabbit | 1:100 for WB |
| β-actin | A3854 ^{\$} , SigmaAldrich | mouse | 1:25,000 for WB |
| HRP-anti-mouse | LNA931V/AG, GE Healthcare UK ltd. | | 1:5000 for WB |
| HRP anti-rabbit | LNA934V/AG, GE Healthcare UK ltd | | 1:5000 for WB |
| anti-rabbit IgG Alexa Fluor 488 | A21206, Invitrogen | donkey | 1:200 for IF |
| anti-mouse IgG Alexa Fluor 594 | A21203, Invitrogen | donkey | 1:200 for IF |

2ST: Antibodies used for western blotting and immunofluorescence microscopy

\$: Peroxidase-linked antibody, usage of secondary antibodies was not applied

3ST: Influence of WY-14643 (300 μ M) and combination with GW6471 (10 μ M) on mRNA expression of PPAR α , PPAR γ , matrixmetalloproteinases MMP-2, -3 and -9, and TIMP-1 and TIMP-3, SOD1 and LRP1 of cerebEND cells; NC6 = cerebEND cells 4h normoxia with C6-medium, OC6 = cerebEND cells 4h OGD with C6-OGD medium. Data are presented as means ± SEM (n=4-8). Statistical significance was labelled with * versus NC6, #: significant versus OC6, §: significant to OC6+WY-14643 (p<0.05).

| | NC6 | OC6 | OC6 +WY-14643 | OC6 + WY-14643 |
|--------|---|---------------------|---------------------|----------------------|
| | | | | + GW6471 |
| PPARa | 2.08 ± 0.38 | $1.00 \pm 0.05^{*}$ | 0.76 ± 0.06*# | 1.08 ± 0.10 |
| ΡΡΑRγ | 0.75 ± 0.04 | $1.00 \pm 0.06^{*}$ | 1.18 ± 0.02*# | $1.05 \pm 0.02*$ § |
| MMP-2 | 1.29 ± 0.08 | $1.00 \pm 0.05*$ | $0.93 \pm 0.07*$ | $0.92 \pm 0.06^{*}$ |
| MMP-3 | 1.24 ± 0.11 | $1.00 ~\pm~ 0.09$ | $0.75 \pm 0.05*$ # | $0.71 \pm 0.05*\#$ |
| MMP-9 | 0.83 ± 0.07 | 1.00 ± 0.12 | $0.92 \ \pm \ 0.12$ | 1.04 ± 0.13 |
| TIMP-1 | 1.05 ± 0.05 | $1.00 \ \pm \ 0.10$ | $0.68 \pm 0.03*$ # | $0.48 \pm 0.03*\#$ § |
| TIMP-3 | $0.81 \hspace{.1in} \pm \hspace{.1in} 0.01$ | 1.00 ± 0.11 | $1.19 \pm 0.01^{*}$ | $1.37 \pm 0.02*\#$ |
| SOD1 | $1.23 \hspace{.1in} \pm \hspace{.1in} 0.07$ | $1.00 \pm 0.03^{*}$ | $0.84 \pm 0.05*$ # | $0.86 \pm 0.03*\#$ |
| LRP1 | 1.66 ± 0.24 | $1.00 \pm 0.02^{*}$ | $0.67 \pm 0.02*$ # | $0.45 \pm 0.04*\#$ § |

4ST: Influence of WY-14643 (300 μ M) on mRNA expression of t-PA, PAI-1, ANGPT1, PDGFb, GDNF, ApoE and TNF α of C6 cells; normoxia = C6 cells 4h normoxia, OGD = C6 cells 4h OGD. Data are presented as means \pm SEM (n=6). Statistical significance was labelled with * versus normoxia, #: significant versus OGD (p<0.05).

| | normoxia | OGD | OGD +WY-14643 |
|--------|---|---------------------|--------------------|
| t-PA | 1.25 ± 0.04 | $1.00 \pm 0.02^{*}$ | 1.24 ± 0.04# |
| PAI-1 | 0.84 ± 0.02 | $1.00 \pm 0.02*$ | 1.73 ± 0.11*# |
| ANGPT1 | $2.11 \hspace{.1in} \pm \hspace{.1in} 0.16$ | $1.00 \pm 0.03^{*}$ | 1.89 ± 0.23# |
| PDGFb | 1.16 ± 0.04 | $1.00 \pm 0.01^{*}$ | $0.77 \pm 0.02*\#$ |
| GDNF | $0.39 ~\pm~ 0.01$ | $1.00 \pm 0.01^{*}$ | $0.82 \pm 0.03*$ # |
| АроЕ | $0.84~\pm~0.07$ | 1.00 ± 0.03 | $0.71 \pm 0.09 $ |
| TNFα | 0.28 ± 0.03 | $1.00 \pm 0.03^{*}$ | $1.84 \pm 0.16*#$ |



S1F: Immunofluorescence images of cerebEND cells treated with 300µM WY-14643 show that PPARalpha was translocated by WY-14643 into the nucleus area. PPARalpha was stained in green, DAPI (blue) to display DNA, nuclei pore protein lamin A was red.

Supplementary figure SF2



S2F: Influence of WY-14643 and PPAR α antagonist GW6471 on effects of OC6 treatment on the protein expression of plasma membrane marker Na⁺/K⁺-ATPase of cerebEND cells. OC6 treatment of cerebENDs accords to four hours OGD treatment with medium supernatants derived from four hours OGD-treated C6 cells, whereas NC6 treatment means cerebEND cells incubated for four hours under normoxic conditions with medium supernatants of four hours normoxic treated C6 cells. Dotted lines indicated cuts of images of the same blot due to presentation reasons of selected bands.

Plasma membrane marker Na^+/K^+ -ATPase was significantly stronger found in the triton-X 100 fraction indicating an enrichment of membrane proteins in the triton-X 100 fraction, whereas cytoskeleton protein β -actin was preferentially found in the RIPA-fraction.

Method description

Immunofluorescence micropscopy

Immunofluorescence microscopy was carried out as published recently (Neuhaus et al., 2014; Neuhaus et al., 2008; Neuhaus et al., 2012b) Applied primary and secondary antibodies could be found in supplementary table 2S. Images were generated by using a Biorevo Keyence BZ-9000 microscope and analyzed with the BZ-II Analyser software.